Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2831150 | 0.95 | CYP1A2 (0.32) | CYP1A2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2827462 | 0.95 | CYP1A2 (0.32) | CYP1A2SIGMAR1 | |
| SCHEMBL20136163 | 0.95 | CYP1A2 (0.35) | CYP1A2SIGMAR1 | |
| SCHEMBL142694 | 0.95 | CYP1A2 (0.35) | CYP1A2SIGMAR1 | |
| SCHEMBL23391375 | 0.92 | CYP1A2 (0.33) | CYP1A2SIGMAR1 | |
| Phosphine SCHEMBL31470123 | 0.92 | CYP1A2 (0.33) | CYP1A2SIGMAR1 | |
| SCHEMBL3720516 | 0.92 | CYP1A2 (0.31) | CYP1A2 | |
| Bromide SCHEMBL2828926 | 0.89 | — | — | |
| SCHEMBL20136165 | 0.89 | — | — | |
| SCHEMBL220818 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100185019-A1 | CATALYST COMPOSITION AND PROCESS FOR PRODUCING CROSS-COUPLED COMPOUND USING SAME | TOSOH FINECHEM CORPORATION (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2168680-A1 | CATALYST COMPOSITION AND METHOD FOR PRODUCING CROSS-COUPLING COMPOUND USING THE SAME | Kyoto University (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185019-A1 | CATALYST COMPOSITION AND PROCESS FOR PRODUCING CROSS-COUPLED COMPOUND USING SAME | PYM1, CHRM2, CHRM1 | CYP1A2 420/4885SIGMAR1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.